Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives Average Rating of “Moderate Buy” from Brokerages

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) has earned an average recommendation of “Moderate Buy” from the seven analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $8.00.

HOWL has been the topic of several research reports. Zacks Research raised shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. JMP Securities decreased their price target on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 21st. Bank of America decreased their price target on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, August 25th. Finally, Citigroup reissued a “buy” rating on shares of Werewolf Therapeutics in a research note on Monday, August 25th.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in HOWL. Vontobel Holding Ltd. purchased a new position in shares of Werewolf Therapeutics during the first quarter worth approximately $34,000. Charles Schwab Investment Management Inc. increased its stake in shares of Werewolf Therapeutics by 33.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock worth $93,000 after buying an additional 23,852 shares during the period. Nuveen LLC purchased a new position in shares of Werewolf Therapeutics in the first quarter worth $71,000. MPM Asset Management LLC increased its stake in shares of Werewolf Therapeutics by 0.6% in the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock worth $4,189,000 after buying an additional 25,688 shares during the period. Finally, MPM Bioimpact LLC increased its stake in shares of Werewolf Therapeutics by 0.9% in the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock worth $2,341,000 after buying an additional 20,799 shares during the period. 64.84% of the stock is owned by hedge funds and other institutional investors.

Werewolf Therapeutics Trading Down 0.6%

Shares of HOWL opened at $1.61 on Wednesday. The firm’s 50 day simple moving average is $1.58 and its 200 day simple moving average is $1.26. The company has a market capitalization of $73.63 million, a P/E ratio of -0.98 and a beta of 0.76. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.30 and a quick ratio of 5.30. Werewolf Therapeutics has a 1-year low of $0.60 and a 1-year high of $4.18.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its earnings results on Thursday, August 14th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.10. Sell-side analysts forecast that Werewolf Therapeutics will post -1.56 earnings per share for the current fiscal year.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.